Navigation Links
TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical

DOYLESTOWN, Pa., Sept. 17 /PRNewswire/ -- Following the recent CE Mark certification of the vProtect(TM) Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and roundtable discussions on lesion-specific therapy for coronary artery disease at TCT 2009, September 21-25, San Francisco, CA. The vPredict(TM) Optical Catheter System, a diagnostic device, also from Prescient Medical, will be featured in several presentations.

All sessions will be held at the Moscone Center. Media contacts welcome. Executives from Prescient Medical will be available to answer questions in advance or following sessions.

8:00 am-6:45 pm, Room 131, Monday, September 21st:

Both devices will be discussed in the day-long scientific symposium "Vulnerable Plaque: Emerging Direction for Diagnosis and Treatment." Professor Patrick W. Serruys of Erasmus Medical Center in Rotterdam will discuss clinical experience with the vProtect(TM) Luminal Shield in stabilizing vulnerable plaque at 5:05 pm. Prof Serruys commented, "Recent developments in the field of vulnerable plaque are very exciting." He added, "We are finally making progress in characterizing, understanding, and potentially treating these lesions." Other key presentations include discussions of preclinical and clinical studies by Juan Granada, MD, of the Cardiovascular Research Foundation, and Giuseppe Sangiorgi, MD, Director of Interventional Cardiology at the University of Rome at 9:00 am, 3:30 pm, and 4:45 pm.

4:00 pm-4:20 pm, Room 134, Wednesday, September 23rd:

Dr. Granada, will present key findings relating to the low-injury self-expanding design of the vProtect(TM) Luminal Shield during "Coronary Stent Design and Device Development."

4:45 pm-4:55 pm, Room 133, Thursday, September 24th:

Dr. Granada will present additional data on the vProtect(TM) Luminal Shield during "The Re-Emergence of Nitinol Self-Expanding Coronary Stents," a special session dedicated to exploring the re-emergence of self-expanding coronary stents led by the vProtect(TM) Luminal Shield. Dr. Granada commented, "It has become clear that stent designs and materials should be tailored to the pathophysiology of the lesion to be treated. The Shield is designed specifically to minimize arterial injury and its consequences, making it ideal for softer plaques."

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. The company is the recipient of the 2009 Frost and Sullivan Award for Product Innovation of the Year Award for vProtect(TM) Luminal Shield. For more information about Prescient Medical and its products, please visit

SOURCE Prescient Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
2. 4th BTLtec Conference on 24-25 Sep in Graz, Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies, Syngas Application, BTL Value Chain and a Site Visit to the Biomass CHP Gussing Plant.
3. Magellan Diagnostic Businesses to Feature Automated Systems and Diagnostic Tests at Clinical Lab Expo
4. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
5. New Scientific Worldview Biocentrism Featured in The Huffington Post - #1 Weblog in the World
6. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
7. NeoStem Featured in Business Week; Promising Adult Stem Cell Market Discussed in Article
8. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
9. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
10. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
11. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):